CGS 15435A
Latest Information Update: 08 Aug 1994
At a glance
- Originator Novartis
- Class Anti-ischaemics; Antithrombotics
- Mechanism of Action Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arterial thrombosis; Ischaemic heart disorders